On Jul. 11, 1999, Daiichi Sankyo and Eli Lilly announced the FDA approved Effientﾙ(prasugrel) tablets for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI). PCI usually includes the placement of a stent to help keep the artery open. /p>